NovoCure NVCR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from NovoCure’s reported figures.
Based on trailing twelve months.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's EBITDA margin?
- NovoCure (NVCR) reported EBITDA margin of -24.9% in Q1 2026.
- How has NovoCure's EBITDA margin changed year-over-year?
- NovoCure's EBITDA margin increased by 0.2% year-over-year, from -24.9% to -24.9%.
- What is the long-term trend for NovoCure's EBITDA margin?
- Over 5 years (2020 to 2025), NovoCure's EBITDA margin has grown at a 21.6% compound annual growth rate (CAGR), from 8% to -21.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.